JP2019530453A - C9orf72座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物 - Google Patents
C9orf72座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物 Download PDFInfo
- Publication number
- JP2019530453A JP2019530453A JP2019517273A JP2019517273A JP2019530453A JP 2019530453 A JP2019530453 A JP 2019530453A JP 2019517273 A JP2019517273 A JP 2019517273A JP 2019517273 A JP2019517273 A JP 2019517273A JP 2019530453 A JP2019530453 A JP 2019530453A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- human animal
- cell
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001465754 Metazoa Species 0.000 title claims description 98
- 238000000034 method Methods 0.000 claims abstract description 161
- 241000283984 Rodentia Species 0.000 claims abstract description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 52
- 239000000126 substance Substances 0.000 claims abstract description 39
- 201000010099 disease Diseases 0.000 claims abstract description 34
- 208000024891 symptom Diseases 0.000 claims abstract description 15
- 229940124598 therapeutic candidate Drugs 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 260
- 108090000623 proteins and genes Proteins 0.000 claims description 195
- 101150014718 C9orf72 gene Proteins 0.000 claims description 174
- 102000043334 C9orf72 Human genes 0.000 claims description 173
- 108700030955 C9orf72 Proteins 0.000 claims description 173
- 150000007523 nucleic acids Chemical class 0.000 claims description 161
- 102000039446 nucleic acids Human genes 0.000 claims description 142
- 108020004707 nucleic acids Proteins 0.000 claims description 142
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 107
- 108020004414 DNA Proteins 0.000 claims description 91
- 102000004169 proteins and genes Human genes 0.000 claims description 83
- 230000014509 gene expression Effects 0.000 claims description 76
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 75
- 108020005004 Guide RNA Proteins 0.000 claims description 68
- 210000004102 animal cell Anatomy 0.000 claims description 60
- 238000003556 assay Methods 0.000 claims description 60
- 239000003814 drug Substances 0.000 claims description 56
- 210000002161 motor neuron Anatomy 0.000 claims description 56
- 238000003780 insertion Methods 0.000 claims description 47
- 230000037431 insertion Effects 0.000 claims description 47
- 125000003729 nucleotide group Chemical group 0.000 claims description 43
- 239000000523 sample Substances 0.000 claims description 43
- 239000002773 nucleotide Substances 0.000 claims description 42
- 210000002569 neuron Anatomy 0.000 claims description 40
- 210000004958 brain cell Anatomy 0.000 claims description 33
- 108091033409 CRISPR Proteins 0.000 claims description 29
- 210000001161 mammalian embryo Anatomy 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 27
- 210000004602 germ cell Anatomy 0.000 claims description 27
- 238000003753 real-time PCR Methods 0.000 claims description 27
- 108010016626 Dipeptides Proteins 0.000 claims description 26
- 230000001965 increasing effect Effects 0.000 claims description 25
- 108010091086 Recombinases Proteins 0.000 claims description 21
- 210000002064 heart cell Anatomy 0.000 claims description 21
- 210000000663 muscle cell Anatomy 0.000 claims description 21
- 108091028113 Trans-activating crRNA Proteins 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 102000018120 Recombinases Human genes 0.000 claims description 17
- 239000003550 marker Substances 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 206010059866 Drug resistance Diseases 0.000 claims description 14
- 238000007901 in situ hybridization Methods 0.000 claims description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 11
- 108020005544 Antisense RNA Proteins 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 239000003184 complementary RNA Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000006798 recombination Effects 0.000 claims description 5
- 238000005215 recombination Methods 0.000 claims description 5
- 230000013011 mating Effects 0.000 claims description 4
- 238000010354 CRISPR gene editing Methods 0.000 claims 11
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract description 33
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract description 25
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 22
- 230000004770 neurodegeneration Effects 0.000 abstract description 14
- 230000008685 targeting Effects 0.000 description 77
- 235000018102 proteins Nutrition 0.000 description 75
- 241000699666 Mus <mouse, genus> Species 0.000 description 70
- 108090000765 processed proteins & peptides Proteins 0.000 description 59
- 239000013598 vector Substances 0.000 description 59
- 229920001184 polypeptide Polymers 0.000 description 58
- 102000004196 processed proteins & peptides Human genes 0.000 description 58
- 241000700159 Rattus Species 0.000 description 51
- 229940079593 drug Drugs 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 41
- 230000004048 modification Effects 0.000 description 36
- 238000012986 modification Methods 0.000 description 36
- 108091079001 CRISPR RNA Proteins 0.000 description 29
- 108091026890 Coding region Proteins 0.000 description 27
- 238000006467 substitution reaction Methods 0.000 description 27
- 239000000203 mixture Substances 0.000 description 25
- 230000014616 translation Effects 0.000 description 24
- 238000013519 translation Methods 0.000 description 23
- 230000000692 anti-sense effect Effects 0.000 description 22
- 210000000287 oocyte Anatomy 0.000 description 21
- 230000001717 pathogenic effect Effects 0.000 description 21
- 102000040430 polynucleotide Human genes 0.000 description 21
- 108091033319 polynucleotide Proteins 0.000 description 21
- 239000002157 polynucleotide Substances 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 20
- 238000012239 gene modification Methods 0.000 description 20
- 108700008625 Reporter Genes Proteins 0.000 description 19
- 230000005017 genetic modification Effects 0.000 description 19
- 235000013617 genetically modified food Nutrition 0.000 description 19
- 208000035475 disorder Diseases 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 238000002744 homologous recombination Methods 0.000 description 17
- 230000006801 homologous recombination Effects 0.000 description 17
- 108700024394 Exon Proteins 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 101000989501 Homo sapiens Guanine nucleotide exchange factor C9orf72 Proteins 0.000 description 15
- 101100383813 Mus musculus C9orf72 gene Proteins 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 210000002257 embryonic structure Anatomy 0.000 description 15
- 102000045815 human C9orf72 Human genes 0.000 description 15
- 108700028369 Alleles Proteins 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 14
- 238000010166 immunofluorescence Methods 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 12
- 230000009261 transgenic effect Effects 0.000 description 12
- 101710163270 Nuclease Proteins 0.000 description 11
- 238000010171 animal model Methods 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 210000004940 nucleus Anatomy 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 210000004413 cardiac myocyte Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 210000005260 human cell Anatomy 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 241001529936 Murinae Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 238000000520 microinjection Methods 0.000 description 8
- 101100383812 Homo sapiens C9orf72 gene Proteins 0.000 description 7
- 238000002105 Southern blotting Methods 0.000 description 7
- 108091081024 Start codon Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 210000003527 eukaryotic cell Anatomy 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 210000000472 morula Anatomy 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000007702 DNA assembly Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 5
- -1 C-5 propynyl-uridine Chemical compound 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 108060002716 Exonuclease Proteins 0.000 description 5
- 108010025815 Kanamycin Kinase Proteins 0.000 description 5
- 229930193140 Neomycin Natural products 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 102000013165 exonuclease Human genes 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 229960004927 neomycin Drugs 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- 229950010131 puromycin Drugs 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000003151 transfection method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 241000699694 Gerbillinae Species 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000016285 Movement disease Diseases 0.000 description 4
- 241001045988 Neogene Species 0.000 description 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 108090000848 Ubiquitin Proteins 0.000 description 4
- 102000044159 Ubiquitin Human genes 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 101150038500 cas9 gene Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000007159 enucleation Effects 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 101150066555 lacZ gene Proteins 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000007659 motor function Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 101100356230 Escherichia coli (strain K12) recT gene Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 208000019155 Radiation injury Diseases 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000005782 double-strand break Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 101150091879 neo gene Proteins 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 101150084750 1 gene Proteins 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 101100355997 Bacillus subtilis (strain 168) recA gene Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010045123 Blasticidin-S deaminase Proteins 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108091005941 EBFP Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 101100301301 Escherichia coli (strain K12) recE gene Proteins 0.000 description 2
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 241001452677 Ogataea methanolica Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108010052160 Site-specific recombinase Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000002242 embryoid body Anatomy 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 108010021843 fluorescent protein 583 Proteins 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000000688 human artificial chromosome Anatomy 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 150000004713 phosphodiesters Chemical group 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108010045647 puromycin N-acetyltransferase Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000005783 single-strand break Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 210000004340 zona pellucida Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 1
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- LMMLLWZHCKCFQA-UGKPPGOTSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-prop-1-ynyloxolan-2-yl]pyrimidin-2-one Chemical compound C1=CC(N)=NC(=O)N1[C@]1(C#CC)O[C@H](CO)[C@@H](O)[C@H]1O LMMLLWZHCKCFQA-UGKPPGOTSA-N 0.000 description 1
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 241000699725 Acomys Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000006822 Agouti Signaling Protein Human genes 0.000 description 1
- 108010072151 Agouti Signaling Protein Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150018129 CSF2 gene Proteins 0.000 description 1
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 1
- 241000700192 Calomyscus sp. Species 0.000 description 1
- 241000722731 Carex Species 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091005944 Cerulean Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000579895 Chlorostilbon Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 101150074775 Csf1 gene Proteins 0.000 description 1
- 241000484025 Cuniculus Species 0.000 description 1
- 108091005943 CyPet Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101000860092 Francisella tularensis subsp. novicida (strain U112) CRISPR-associated endonuclease Cas12a Proteins 0.000 description 1
- 101150106478 GPS1 gene Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 101150007884 Gata6 gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101150002416 Igf2 gene Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 101150040658 LHX2 gene Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 241000699669 Mus saxicola Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000380800 Nordus Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000736285 Sphagnum Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101710177717 Terminase small subunit Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 101710159648 Uncharacterized protein Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000006743 cytoplasmic accumulation Effects 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 208000013967 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 Diseases 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 101150003286 gata4 gene Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150115794 lhx5 gene Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 150000002678 macrocyclic compounds Chemical group 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008904 neural response Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000001508 sulfur Nutrition 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Environmental Sciences (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本出願は、2016年9月30日に出願された米国仮特許出願第62/402,613号、および2017年1月31日に出願された米国仮特許出願第62/452,795号の利益を主張するものであり、各仮特許出願は、参照によりその全体が本明細書に組み込まれる。
配列表の参照による組み込み
本発明は本明細書に記載された特定の方法および実験条件に限定されないが、それはこのような方法および条件は変化する場合があるからである。本発明の範囲は請求項によって定義されるので、本明細書に使用される用語は、特定の実施形態のみを記載する目的で使用されており、限定を意図しないことも理解される。
[発明を実施するための形態]
C9ORF72
C9ORF72およびヘキサヌクレオチドリピート伸長配列
A.大型標的化ベクター
B.大型標的化ベクターの構築
C.C9orf72−HRE核酸構築物
E.標的の遺伝子改変を有する細胞のスクリーニングおよび特定
F.遺伝子改変非ヒト動物を作製する方法
内因性C9ORF72座位中に異種ヘキサヌクレオチドリピート伸長配列の挿入を有する非ヒト動物を使用する方法
実施例1 非ヒト胚性幹細胞において、内因性非ヒトC9ORF72座位に異種ヘキサヌクレオチドリピート伸長配列を挿入する
(5’−CCGGGGCGGGGCTGCGGTTGCGGTGCCTGCGCCCGCGGCGGCGGAGGCGCAGGCGGTGGCGAGTGGGTGAGTGAGGAGGCGGCATCCTGGCGGGTGGCTGTTTGGGGTTCGGCTGCCGGGAAGAGGCGCGGGTAGAAGCGGGGGCTCTCCTCAGAGCTCGACGCATTTTTACTTTCCCTCTCATTTCTCTGACCGAAGCTGGGTGTCGGGCTTTCGCCTCTAGCGACTGGTGGAATTGCCTGCATCCGGGCC−3’;(配列番号29)を、
Prime−It II Random Primer Labeling Kit(Agilent社)を使用して32Pで標識した。変性させたプローブをExpressHyb Hybridization Solution(Takara社)中で希釈し、調整済み膜とともに65℃で一晩インキュベートした。オートラジオグラフィーフィルムを72時間、プローブが付着したブロットに暴露させた。
表4
実施例2:内因性マウスC9ORF72座位で異種ヘキサヌクレオチドリピート伸長配列を含有する胚性幹細胞から誘導された運動ニューロンおよび非ヒト動物の作製
実施例3 内因性C9orf72座位中に異種ヘキサヌクレオチドリピート伸長配列を有する運動ニューロンまたは脳組織の解析
表5
表6
実施例4 内因性C9orf72座位に異種ヘキサヌクレオチドリピート伸長配列を有する非ヒト動物の行動解析
実施例5 CRISPR/Cas9システムを使用して、非ヒト胚性幹細胞中の内因性非ヒトC9ORF72座位から異種ヘキサヌクレオチドリピート伸長配列を除去する
均等
Claims (51)
- そのゲノム中に内因性C9orf72座位内に挿入された異種ヘキサヌクレオチドリピート伸長配列を含む非ヒト動物または非ヒト動物細胞であって、前記配列は、前記異種ヘキサヌクレオチドリピート伸長配列は、配列番号1として明記される前記ヘキサヌクレオチド配列のリピートを少なくとも一個含有する、非ヒト動物または非ヒト動物細胞。
- 前記異種ヘキサヌクレオチドリピート伸長配列は、配列番号1として明記される前記ヘキサヌクレオチド配列のリピートを少なくとも30個含有する、請求項1に記載の非ヒト動物または非ヒト動物細胞。
- 前記ヘキサヌクレオチドリピート伸長は、配列番号1として明記される前記ヘキサヌクレオチド配列のリピートを少なくとも90個含有する、請求項1または請求項2に記載の非ヒト動物または非ヒト動物細胞。
- 前記非ヒト動物または非ヒト動物細胞が、(i)野生型C9orf72座位を含有する対照動物と比較してC9orf72転写物発現の増加、(ii)野生型C9orf72座位を含有する対照動物と比較してRNA凝集体数の増加、(iii)野生型C9orf72座位を含有する対照動物と比較してジペプチドリピートタンパク質レベルの増加、または(iv)(i)〜(iii)の任意の組み合わせ、を示す、請求項1〜3のいずれか一項に記載の非ヒト動物または非ヒト動物細胞。
- 前記異種ヘキサヌクレオチドリピート伸長配列が、内因性C9orf72座位の最初の非コード内因性エクソンとエクソン2の間に位置付けられる、請求項1〜4のいずれか一項に記載の非ヒト動物または非ヒト動物細胞。
- 前記内因性C9orf72座位が、配列番号2、配列番号3、配列番号4、配列番号5、配列番号6、配列番号7として明記されるヌクレオチド配列、またはそのバリアントを含有する、請求項5に記載の非ヒト動物または非ヒト動物細胞。
- 前記非ヒト動物が、齧歯類であるか、または前記非ヒト動物細胞が、齧歯類細胞である、請求項1〜6のいずれか一項に記載の非ヒト動物または非ヒト動物細胞。
- 前記齧歯類がラットもしくはマウスであるか、または前記非ヒト動物細胞がラット細胞もしくはマウス細胞である、請求項7に記載の非ヒト動物または非ヒト動物細胞。
- 前記非ヒト動物がマウスであるか、または前記非ヒト動物細胞がマウス細胞であり、前記異種ヘキサヌクレオチドリピート伸長配列が配列番号1として明記される前記ヘキサヌクレオチド配列のリピートを92個含有し、ならびに前記マウスまたはマウス細胞が、以下の三つの特徴、(i)野生型C9orf72座位を含有する対照動物と比較してC9orf72転写物発現の増加、(ii)野生型C9orf72座位を含有する対照動物と比較してRNA凝集体数の増加、および(iii)野生型C9orf72座位を含有する対照動物と比較してジペプチドリピートタンパク質レベルの増加、のすべてを示す、請求項8に記載の非ヒト動物または非ヒト動物細胞。
- 前記非ヒト動物が、前記異種ヘキサヌクレオチドリピート伸長配列に対してホモ接合性である、請求項1〜9のいずれかに記載の非ヒト動物または非ヒト動物細胞。
- 前記非ヒト動物が、前記異種ヘキサヌクレオチドリピート伸長配列に対してヘテロ接合性である、請求項1〜9のいずれか一項に記載の非ヒト動物または非ヒト動物細胞。
- 前記異種ヘキサヌクレオチドリピート伸長配列が、第一の異種ヘキサヌクレオチド伸長配列であり、前記非ヒト動物または非ヒト動物細胞が、第二の異種ヘキサヌクレオチドリピート伸長配列に対してもヘテロ接合性であり、前記第一の伸長配列が、前記第二の異種ヘキサヌクレオチドリピート伸長配列とは異なるリピート数を有する、請求項11に記載の非ヒト動物または非ヒト動物細胞。
- 前記第一の異種リピート伸長配列が、配列番号1として明記される前記ヘキサヌクレオチド配列のリピートを1〜3個含有し、前記第二の異種リピート伸長配列が、配列番号1として明記されるヘキサヌクレオチド配列のリピートを4〜100個含有する、請求項12に記載の非ヒト動物または非ヒト動物細胞。
- 前記非ヒト動物細胞が、胚性幹細胞、胚性幹細胞から誘導された運動ニューロン、脳細胞、皮質細胞、神経細胞、筋細胞、心細胞、または生殖細胞である、請求項1〜13のいずれか1項に記載の非ヒト動物または非ヒト動物細胞。
- 請求項14に記載の胚性幹細胞から誘導された不死化細胞株または運動ニューロン。
- そのゲノムが内因性C9orf72座位中に異種ヘキサヌクレオチドリピート伸長配列を含む非ヒト動物胚性幹細胞であって、前記異種ヘキサヌクレオチドリピート伸長配列は、配列番号1として明記されるヘキサヌクレオチド配列のリピートを少なくとも一個含有する、非ヒト動物胚性幹細胞。
- 請求項16に記載の胚性幹細胞から作製される非ヒト動物胚。
- そのゲノムがヘキサヌクレオチド配列を含む非ヒト動物の作製方法であって、前記方法が、
そのゲノムが内因性C9orf72座位中に異種ヘキサヌクレオチドリピート伸長配列を含むように、前記非ヒト動物のゲノムを改変することであって、前記異種ヘキサヌクレオチドリピート伸長配列は、配列番号1として明記される前記ヘキサヌクレオチド配列のリピートを少なくとも一個含有する、改変することを含む、方法。 - 前記改変することが、
(a)挿入核酸を含む核酸構築物を非ヒト胚性幹細胞内に導入することであって、前記挿入核酸は、5’から3’方向に、(i)前記C9orf72座位の5’標的配列に対して相同な5’相同アーム、(ii)異種ヘキサヌクレオチドリピート伸長配列、および(iii)前記C9orf72座位の5’標的配列に対して相同な3’相同アーム、を含有する、導入すること、
(b) (a)から遺伝子改変された齧歯類胚性幹細胞を取得すること、および、
(c) (b)の前記遺伝子改変された齧歯類胚性幹細胞を使用して齧歯類を作製すること、を含むプロセスにより達成される、請求項18に記載の方法。 - 前記挿入核酸が、5’相同アームと3’相同アームの間に、一つ以上の選択マーカーをコードする一つ以上の遺伝子をさらに含む、請求項19に記載の方法。
- 前記挿入核酸が、5’相同アームと3’相同アームの間に、一つ以上の部位特異的組み換え部位をさらに含む、請求項19または20に記載の方法。
- 前記挿入核酸が、5’相同アームと3’相同アームの間に、リコンビナーゼ認識部位に隣接したリコンビナーゼ遺伝子と選択マーカーをさらに含み、前記リコンビナーゼ認識部位は、除去を誘導するよう方向づけられる、請求項21に記載の方法。
- 前記5’相同アームが、前記内因性C9orf72座位のエクソン1またはその一部に対して同一であるか、または実質的に同一である、請求項19〜22のいずれか一項に記載の方法。
- 前記5’相同アームが、配列番号20または配列番号23として明記される前記ヌクレオチド配列を含む、請求項23に記載の方法。
- 前記3’相同アームが、前記内因性C9orf72座位のイントロン1の少なくとも一部に対して同一であるか、または実質的に同一である、請求項19〜24のいずれか一項に記載の方法。
- 前記3’相同アームが、配列番号22または配列番号25として明記される前記ヌクレオチド配列を含む、請求項25に記載の方法。
- 前記挿入核酸が、配列番号2または配列番号4として明記される核酸配列を含む、請求項18〜26のいずれか一項に記載の方法。
- 前記挿入核酸が、配列番号3または配列番号6として明記される核酸配列を含む、請求項18〜26のいずれか一項に記載の方法。
- 前記挿入に対しホモ接合性の齧歯類が作製されるように、(c)で作製された前記齧歯類を交配させる工程をさらに含む、請求項18〜28のいずれか一項に記載の方法。
- 前記非ヒト動物が齧歯類である、請求項18〜29のいずれか一項に記載の方法。
- 前記齧歯類がマウスまたはラットである、請求項30に記載の方法。
- 請求項18〜31のいずれか一項に記載の方法により取得可能な非ヒト動物。
- ヘキサヌクレオチドリピート伸長配列の存在と関連した疾患または状態の治療のための治療剤候補物質を特定する方法であって、
(a)候補物質を、配列番号1として明記された前記ヘキサヌクレオチド配列のリピートを少なくとも一個含むヘキサヌクレオチドリピート伸長配列を含むよう遺伝子改変されたC9ORF72座位を含む非ヒト動物または非ヒト動物細胞に投与すること、
(b)前記候補物質が前記疾患または状態に関連した兆候、症状および/または状態の一つ以上に対する効果を有するかどうかを決定するためのアッセイを1種以上実施しすること、および
(c)前記疾患または状態と関連した兆候、症状および/または状態に対する効果を有する前記候補物質を前記治療剤候補物質として特定すること、を含む、方法。 - 前記候補物質が、非ヒト動物にin vivoで投与され、および任意で、前記アッセイが、前記候補物質の投与後に前記非ヒト動物から単離された組織に対してin vitroで行われる、請求項33に記載の方法。
- 前記候補物質が、非ヒト胚性幹細胞から誘導された運動ニューロンに対してin vitroで投与される、請求項33に記載の方法。
- 前記アッセイが、C9orf72遺伝子産物を検出する定量的ポリメラーゼ連鎖反応(qPCR)である、請求項33〜35のいずれか一項に記載の方法。
- qPCRは、配列番号66、配列番号67、配列番号68、配列番号69、配列番号70、配列番号71、配列番号72、配列番号73、配列番号74、配列番号75、配列番号76、配列番号77、配列番号78、配列番号79、配列番号80、またはそれらの任意の組み合わせに明記されるヌクレオチド配列を有するプライマーおよび/またはプローブを用いて実施される、請求項36に記載の方法。
- 前記アッセイは、C9orf72のセンスRNA転写物またはアンチセンスRNA転写物を含むRNA凝集体を測定する、請求項33〜35のいずれか一項に記載の方法。
- 前記アッセイは、配列番号81、配列番号82、配列番号83、および/または配列番号84のいずれか一つに明記されるヌクレオチド配列を有するプローブを一つ以上使用した蛍光in situハイブリダイゼーションである、請求項38に記載の方法。
- 前記アッセイは、ポリGAジペプチドリピートタンパク質を測定する、請求項33〜35のいずれか一項に記載の方法。
- 異種ヘキサヌクレオチドリピート伸長配列を含む宿主細胞。
- 前記宿主細胞は、細菌細胞である、請求項41に記載の宿主細胞。
- Casタンパク質および/または一つ以上のgRNAを含むCRISPR/Casシステムであって、前記一つ以上のgRNAは、配列番号38、配列番号39、配列番号40、配列番号41、配列番号42、配列番号43、配列番号44、配列番号45、配列番号46、配列番号47、配列番号48、配列番号49、配列番号50、およびそれらの組み合わせからなる群から選択される配列を含むDNAによりコードされる、CRISPR/Casシステム。
- 前記一つ以上のgRNAが、第一、第二、および第三のgRNAを含み、前記第一のgRNAは、配列番号39として明記される配列を含むDNAによりコードされ、前記第二のgRNAは、配列番号44として明記される配列を含むDNAによりコードされ、および前記第三のgRNAは、配列番号50として明記される配列を含むDNAによりコードされる、請求項43に記載のCRISPR/Casシステム。
- 配列番号47として明記される配列を含むDNAによりコードされる第四のgRNAをさらに含む、請求項44に記載のCRISPR/Casシステム。
- 第五、第六、および第七のgRNAをさらに含み、前記第五のgRNAは、配列番号46として明記される配列を含むDNAによりコードされ、前記第六のgRNAは、配列番号48として明記される配列を含むDNAによりコードされ、および前記第七のgRNAは、配列番号49として明記される配列を含むDNAによりコードされる、請求項45に記載のCRISPR/Casシステム。
- 前記gRNAが、配列番号63、64、または65として明記される配列を含むDNAによりコードされるtracrRNAを含む、請求項42〜46のいずれか一項に記載のCRISPR/Casシステム。
- 前記tracrRNAが、配列番号63として明記される配列を含むDNAによりコードされる、請求項47に記載のCRISPR/Casシステム。
- 前記tracrRNAが、配列番号64として明記される配列を含むDNAによりコードされる、請求項47に記載のCRISPR/Casシステム。
- 前記tracrRNAが、配列番号65として明記される配列を含むDNAによりコードされる、請求項47に記載のCRISPR/Casシステム。
- 発現構築物をさらに含み、前記発現構築物が、前記Casタンパク質をコードする核酸および/または少なくとも一つのgRNAをコードするDNAを含み、任意で前記発現構築物が薬剤抵抗性遺伝子をさらに含む、請求項43〜50のいずれか一項に記載のCRISPR/Casシステム。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662402613P | 2016-09-30 | 2016-09-30 | |
US62/402,613 | 2016-09-30 | ||
US201762452795P | 2017-01-31 | 2017-01-31 | |
US62/452,795 | 2017-01-31 | ||
PCT/US2017/054551 WO2018064600A1 (en) | 2016-09-30 | 2017-09-29 | Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020160492A Division JP2020198894A (ja) | 2016-09-30 | 2020-09-25 | C9orf72座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019530453A true JP2019530453A (ja) | 2019-10-24 |
JP2019530453A5 JP2019530453A5 (ja) | 2020-11-12 |
JP7026678B2 JP7026678B2 (ja) | 2022-02-28 |
Family
ID=60201654
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019517273A Active JP7026678B2 (ja) | 2016-09-30 | 2017-09-29 | C9orf72座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物 |
JP2020160492A Withdrawn JP2020198894A (ja) | 2016-09-30 | 2020-09-25 | C9orf72座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020160492A Withdrawn JP2020198894A (ja) | 2016-09-30 | 2020-09-25 | C9orf72座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US10781453B2 (ja) |
EP (1) | EP3518667A1 (ja) |
JP (2) | JP7026678B2 (ja) |
KR (2) | KR102294755B1 (ja) |
CN (1) | CN109862785B (ja) |
AU (1) | AU2017336100B2 (ja) |
CA (1) | CA3038548A1 (ja) |
IL (2) | IL265669B (ja) |
MX (2) | MX2019003745A (ja) |
RU (1) | RU2760877C2 (ja) |
SG (1) | SG10202102997UA (ja) |
WO (1) | WO2018064600A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014062691A2 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
WO2014062736A1 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Methods for monitoring c9orf72 expression |
WO2015054676A2 (en) | 2013-10-11 | 2015-04-16 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
WO2015143078A1 (en) | 2014-03-18 | 2015-09-24 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
EP3302048B1 (en) | 2015-05-29 | 2020-02-19 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a disruption in a c9orf72 locus |
WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
CN109312339B (zh) * | 2015-12-23 | 2022-01-28 | 克里斯珀医疗股份公司 | 用于治疗肌萎缩侧索硬化症和/或额颞叶变性的材料和方法 |
SG10202102997UA (en) * | 2016-09-30 | 2021-04-29 | Regeneron Pharma | Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus |
WO2018208972A1 (en) * | 2017-05-09 | 2018-11-15 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (als) |
JP7397488B2 (ja) | 2017-09-22 | 2023-12-13 | ユニバーシティ オブ マサチューセッツ | Sod1二重発現ベクターおよびその使用 |
CN111819281A (zh) * | 2017-10-23 | 2020-10-23 | 普利维尔治疗公司 | 用于神经变性疾病的基因疗法 |
WO2019222354A1 (en) * | 2018-05-15 | 2019-11-21 | University Of Washington | Compositions and methods for reducing spliceopathy and treating rna dominance disorders |
JP7449291B2 (ja) | 2018-12-20 | 2024-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヌクレアーゼ媒介リピート伸長 |
EP3725536A1 (en) * | 2019-04-18 | 2020-10-21 | Thales Dis France SA | Security document with double verification lenses |
EP3966328A4 (en) | 2019-05-06 | 2023-10-18 | University Of Massachusetts | ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS |
EP4073251A1 (en) | 2019-12-13 | 2022-10-19 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
US20230040053A1 (en) * | 2019-12-23 | 2023-02-09 | Tsinghua University | DEVELOPMENT OF DUAL-gRNA APPROACH WITH UNDETECTABLE OFF-TARGET EFFECT TO CORRECT C9ORF72 REPEAT EXPANSION AND C9ORF72 PATHOLOGY |
AU2021253183A1 (en) * | 2020-04-09 | 2022-11-03 | Association Institut De Myologie | Antisense sequences for treating amyotrophic lateral sclerosis |
US20230381170A1 (en) * | 2020-10-20 | 2023-11-30 | University Of Florida Research Foundation, Incorporated | Method for treating als/ftd through degradation of rna repeat expansion |
IL308743A (en) | 2021-06-04 | 2024-01-01 | Alnylam Pharmaceuticals Inc | Compositions of human chromosome 9 open reading frame 72 iRNA factor (C9ORF72) and methods of using them |
WO2023077037A1 (en) * | 2021-10-27 | 2023-05-04 | University Of Florida Research Foundation, Incorporated | Small molecule degradation methods for treating als/ftd |
WO2024044493A2 (en) * | 2022-08-22 | 2024-02-29 | The Johns Hopkins University | Treatment of repeat expansion disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015200334A1 (en) * | 2014-06-23 | 2015-12-30 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated dna assembly |
WO2016089692A1 (en) * | 2014-12-05 | 2016-06-09 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 47 gene |
JP2016105730A (ja) * | 2009-08-14 | 2016-06-16 | レビビコア, インコーポレイテッド | 糖尿病の処置のためのマルチ・トランスジェニック・ブタ |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514545A (en) * | 1992-06-11 | 1996-05-07 | Trustees Of The University Of Pennsylvania | Method for characterizing single cells based on RNA amplification for diagnostics and therapeutics |
US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
WO1999005266A2 (en) | 1997-07-26 | 1999-02-04 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AUPR451401A0 (en) | 2001-04-20 | 2001-05-24 | Monash University | A method of nuclear transfer |
US7612250B2 (en) | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
PT1802193E (pt) | 2004-10-19 | 2014-06-23 | Regeneron Pharma | Método para gerar um murganho homozigótico para uma modificação genética |
CN101117633B (zh) | 2006-08-03 | 2011-07-20 | 上海交通大学附属儿童医院 | 一种细胞核移植方法 |
EP3064599B1 (en) | 2008-02-15 | 2018-12-12 | Synthetic Genomics, Inc. | Methods for in vitro joining and combinatorial assembly of nucleic acid molecules |
RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
WO2011020014A1 (en) | 2009-08-14 | 2011-02-17 | Regeneron Pharmaceuticals, Inc. | Promoter-regulated differentiation-dependent self-deleting cassette |
WO2013030588A1 (en) | 2011-08-31 | 2013-03-07 | The University Of Manchester | Method for diagnosing a neurodegenerative disease |
WO2013041577A1 (en) | 2011-09-20 | 2013-03-28 | Vib Vzw | Methods for the diagnosis of amyotrophic lateral sclerosis and frontotemporal lobar degeneration |
EP2847335B1 (en) | 2012-04-25 | 2018-06-27 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
WO2014062736A1 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Methods for monitoring c9orf72 expression |
WO2014062691A2 (en) * | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
EP2906696B2 (en) | 2012-10-15 | 2022-12-14 | Ionis Pharmaceuticals, Inc. | Methods for modulating c9orf72 expression |
US8697359B1 (en) * | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
EP2948471A4 (en) | 2013-01-24 | 2016-08-10 | Mayo Foundation | METHOD AND MATERIALS FOR DETECTING POSITIVE FRONTOTEMPORAL PAPER DEGENERATION BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION OR AMYOTROPHATE LATERAL SCLEROSIS BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION |
ES2904803T3 (es) | 2013-02-20 | 2022-04-06 | Regeneron Pharma | Modificación genética de ratas |
AU2014241078B2 (en) * | 2013-03-14 | 2020-03-12 | University Of Florida Research Foundation, Inc. | Di-amino acid repeat-containing proteins associated with ALS |
PT3456831T (pt) | 2013-04-16 | 2021-09-10 | Regeneron Pharma | Modificação alvejada do genoma de rato |
US10508289B2 (en) | 2013-10-25 | 2019-12-17 | Cellectis | Rare-cutting endonucleases for efficient and specific targeting DNA sequences comprising highly repetitive motives |
JP6625055B2 (ja) | 2013-12-12 | 2020-01-08 | ザ・ブロード・インスティテュート・インコーポレイテッド | 組成物、及びヌクレオチドリピート障害におけるcrispr−cas系の使用方法 |
WO2015143078A1 (en) * | 2014-03-18 | 2015-09-24 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
WO2015153760A2 (en) | 2014-04-01 | 2015-10-08 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a nervous system disorder |
RU2771532C2 (ru) | 2014-06-26 | 2022-05-05 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для нацеленных генетических модификаций и способы их применения |
WO2016025692A1 (en) * | 2014-08-13 | 2016-02-18 | The Scripps Research Institute | Treatment of c9ftd/als by targeting rna expanded repeat sequences |
WO2016024205A1 (en) * | 2014-08-15 | 2016-02-18 | Pfizer Inc. | Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene |
US10538762B2 (en) * | 2014-10-14 | 2020-01-21 | The Board Of Regents Of The University Of Texas System | Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat |
KR20230070319A (ko) | 2014-11-21 | 2023-05-22 | 리제너론 파마슈티칼스 인코포레이티드 | 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물 |
BR112017013104A2 (pt) | 2014-12-19 | 2018-05-15 | Regeneron Pharma | métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano. |
WO2016112132A1 (en) | 2015-01-06 | 2016-07-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
CA2978096C (en) * | 2015-03-16 | 2022-06-28 | Regeneron Pharmaceuticals, Inc. | Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception |
WO2016174056A1 (en) | 2015-04-27 | 2016-11-03 | Genethon | Compositions and methods for the treatment of nucleotide repeat expansion disorders |
DK3289076T3 (da) | 2015-05-01 | 2022-01-17 | Prec Biosciences Inc | Præcis sletning af kromosomale sekvenser in vivo |
EP3302048B1 (en) | 2015-05-29 | 2020-02-19 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a disruption in a c9orf72 locus |
EP3344756A4 (en) | 2015-09-02 | 2019-09-04 | University of Massachusetts | DETECTION OF LOCI OF GENES COMPRISING MATRIX REPETITIONS OF CRISPR AND / OR POLYCHROMATIC MONO-GUIDE RIBONUCLEIC ACIDS |
CN109312339B (zh) * | 2015-12-23 | 2022-01-28 | 克里斯珀医疗股份公司 | 用于治疗肌萎缩侧索硬化症和/或额颞叶变性的材料和方法 |
EP3442596A1 (en) | 2016-04-14 | 2019-02-20 | Université de Lausanne | Treatment and/or prevention of dna-triplet repeat diseases or disorders |
US20190270980A1 (en) | 2016-07-25 | 2019-09-05 | Mayo Foundation For Medical Education And Research | Treating cancer |
SG10202102997UA (en) * | 2016-09-30 | 2021-04-29 | Regeneron Pharma | Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus |
JP7211940B2 (ja) | 2016-10-28 | 2023-01-24 | ジェネトン | 筋緊張性ジストロフィーの治療のための組成物および方法 |
US11427824B2 (en) | 2016-10-28 | 2022-08-30 | Genethon | Compositions and methods for the treatment of myotonic dystrophy |
WO2018165541A1 (en) | 2017-03-10 | 2018-09-13 | The Board Of Regents Of The University Of Texas System | Treatment of fuchs' endothelial corneal dystrophy |
WO2018208972A1 (en) | 2017-05-09 | 2018-11-15 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (als) |
CA3079727A1 (en) | 2017-10-24 | 2019-05-02 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of rare diseases |
-
2017
- 2017-09-29 SG SG10202102997UA patent/SG10202102997UA/en unknown
- 2017-09-29 RU RU2019108888A patent/RU2760877C2/ru active
- 2017-09-29 KR KR1020197011950A patent/KR102294755B1/ko active IP Right Grant
- 2017-09-29 CA CA3038548A patent/CA3038548A1/en active Pending
- 2017-09-29 WO PCT/US2017/054551 patent/WO2018064600A1/en active Application Filing
- 2017-09-29 EP EP17792229.1A patent/EP3518667A1/en active Pending
- 2017-09-29 CN CN201780060178.7A patent/CN109862785B/zh active Active
- 2017-09-29 US US15/721,517 patent/US10781453B2/en active Active
- 2017-09-29 MX MX2019003745A patent/MX2019003745A/es unknown
- 2017-09-29 KR KR1020217026697A patent/KR102527979B1/ko active IP Right Grant
- 2017-09-29 AU AU2017336100A patent/AU2017336100B2/en active Active
- 2017-09-29 JP JP2019517273A patent/JP7026678B2/ja active Active
-
2019
- 2019-03-27 IL IL265669A patent/IL265669B/en unknown
- 2019-03-29 MX MX2021003996A patent/MX2021003996A/es unknown
-
2020
- 2020-08-05 US US16/986,077 patent/US20200370054A1/en active Pending
- 2020-09-25 JP JP2020160492A patent/JP2020198894A/ja not_active Withdrawn
-
2021
- 2021-07-21 IL IL285014A patent/IL285014A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016105730A (ja) * | 2009-08-14 | 2016-06-16 | レビビコア, インコーポレイテッド | 糖尿病の処置のためのマルチ・トランスジェニック・ブタ |
WO2015200334A1 (en) * | 2014-06-23 | 2015-12-30 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated dna assembly |
WO2016089692A1 (en) * | 2014-12-05 | 2016-06-09 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 47 gene |
Non-Patent Citations (2)
Title |
---|
NEURON, vol. 72(2), JPN6020042103, 2011, pages 245 - 256, ISSN: 0004468339 * |
NEURON, vol. 88(5), JPN6020042106, 2015, pages 892 - 901, ISSN: 0004468340 * |
Also Published As
Publication number | Publication date |
---|---|
SG10202102997UA (en) | 2021-04-29 |
RU2019108888A3 (ja) | 2021-01-18 |
CN109862785B (zh) | 2022-09-06 |
JP7026678B2 (ja) | 2022-02-28 |
US20200370054A1 (en) | 2020-11-26 |
CA3038548A1 (en) | 2018-04-05 |
KR20190057104A (ko) | 2019-05-27 |
US10781453B2 (en) | 2020-09-22 |
IL265669A (en) | 2019-05-30 |
AU2017336100B2 (en) | 2023-11-30 |
AU2017336100A1 (en) | 2019-05-23 |
MX2021003996A (es) | 2021-06-23 |
RU2760877C2 (ru) | 2021-12-01 |
IL265669B (en) | 2021-08-31 |
KR102527979B1 (ko) | 2023-04-28 |
KR20210109649A (ko) | 2021-09-06 |
WO2018064600A1 (en) | 2018-04-05 |
KR102294755B1 (ko) | 2021-08-31 |
MX2019003745A (es) | 2019-12-11 |
US20180094267A1 (en) | 2018-04-05 |
CN109862785A (zh) | 2019-06-07 |
JP2020198894A (ja) | 2020-12-17 |
RU2019108888A (ru) | 2020-10-30 |
IL285014A (en) | 2021-08-31 |
EP3518667A1 (en) | 2019-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200370054A1 (en) | Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus | |
AU2021201827B2 (en) | Non-human animals having a disruption in a c9orf72 locus | |
ES2700972T3 (es) | Animales no humanos que tienen un gen de factor activador de células B humanizado | |
KR20170102234A (ko) | 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물 | |
JP2020532952A (ja) | Casトランスジェニックマウスの胚性幹細胞およびマウスならびにその使用 | |
JP7193509B2 (ja) | 上位及び下位運動ニューロン機能並びに知覚の減衰を示す非ヒト動物 | |
JP2019509059A (ja) | 変異型キヌレニナーゼ遺伝子を有する非ヒト動物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200925 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200925 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200925 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20201013 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210319 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210618 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211206 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20211206 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20211213 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20211214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220215 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7026678 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |